Hemant K Bid
Overview
Explore the profile of Hemant K Bid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
741
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shackleford T, Hariharan S, Vaseva A, Alagoa K, Espinoza M, Bid H, et al.
Mol Cancer Ther
. 2023 Jan;
22(4):539-550.
PMID: 36696581
Antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) induce objective responses in only 5% to 15% of children with sarcoma. Understanding the mechanisms of resistance may identify combination therapies that...
2.
Gross A, Cam H, Phelps D, Saraf A, Bid H, Cam M, et al.
JCI Insight
. 2018 Aug;
3(16).
PMID: 30135299
Osteosarcoma (OS), a malignant tumor of bone, kills through aggressive metastatic spread almost exclusively to the lung. Mechanisms driving this tropism for lung tissue remain unknown, though likely invoke specific...
3.
Bid H, Phelps D, Xaio L, Guttridge D, Lin J, London C, et al.
Mol Cancer Ther
. 2016 Feb;
15(5):1018-28.
PMID: 26908627
The bromodomain and extra-terminal domain inhibitor JQ1 has marked antitumor activity against several hematologic malignancies as well as solid tumor models. Here, we investigated its activity in vitro and in...
4.
McCann G, Naidu S, Rath K, Bid H, Tierney B, Suarez A, et al.
Oncoscience
. 2015 Jan;
1(3):216-28.
PMID: 25594014
Tumor hypoxia, a feature of many solid tumors including ovarian cancer, is associated with resistance to therapies. We previously demonstrated that hypoxic exposure results in increased expression of phosphorylated signal...
5.
Wang H, Guo J, West X, Bid H, Lu L, Hong L, et al.
Chem Res Toxicol
. 2014 Nov;
27(12):2015-22.
PMID: 25380349
Oxidation of docosahexaenoate phospholipids produces 4-hydroxy-7-oxo-hept-5-eonyl phospholipids (HOHA-PLs) that react with protein lysyl ε-amino residues to generate 2-ω-carboxyethylpyrrole (CEP) derivatives, endogenous factors that induce angiogenesis in the retina and tumors....
6.
Rath K, Naidu S, Lata P, Bid H, Rivera B, McCann G, et al.
Cancer Res
. 2014 Mar;
74(8):2316-27.
PMID: 24590057
STAT3 is well corroborated preclinically as a cancer therapeutic target, but tractable translational strategies for its blockade by small molecule inhibitors have remained elusive. In this study, we report the...
7.
Cam M, Bid H, Xiao L, Zambetti G, Houghton P, Cam H
J Biol Chem
. 2013 Dec;
289(7):4083-94.
PMID: 24366874
Under conditions of DNA damage, the mammalian target of rapamycin complex 1 (mTORC1) is inhibited, preventing cell cycle progression and conserving cellular energy by suppressing translation. We show that suppression...
8.
Bid H, Roberts R, Cam M, Audino A, Kurmasheva R, Lin J, et al.
Cancer Res
. 2013 Oct;
74(1):320-9.
PMID: 24154873
The tumor suppressor gene p53 and its family members p63/p73 are critical determinants of tumorigenesis. ΔNp63 is a splice variant of p63, which lacks the N-terminal transactivation domain. It is...
9.
Bid H, Kibler A, Phelps D, Manap S, Xiao L, Lin J, et al.
Clin Cancer Res
. 2013 Oct;
19(24):6716-29.
PMID: 24132923
Purpose: The BT-40 low-grade childhood astrocytoma xenograft model expresses mutated BRAF(V600E) and is highly sensitive to the MEK inhibitor selumetinib (AZD6244). In this study, we developed and characterized selumetinib resistance...
10.
Bid H, Roberts R, Manchanda P, Houghton P
Mol Cancer Ther
. 2013 Sep;
12(10):1925-34.
PMID: 24072884
Angiogenesis and metastasis are well recognized as processes fundamental to the development of malignancy. Both processes involve the coordination of multiple cellular and chemical activities through myriad signaling networks, providing...